CING

Cingulate Inc

Add to Watchlist

Advanced Chart

3.700

-0.03(-0.804%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.870

Open

3.810

VWAP

3.71

Vol

175.72K

Mkt Cap

20.03M

Low

3.630

Amount

652.73K

EV/EBITDA(TTM)

Total Shares

6.50M

17.83M

EV/OCF(TTM)

P/S(TTM)

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.647

-37.82%

-0.646

-71.91%

-0.752

-58.91%

Estimates Revision

The market is revising No Change the revenue expectations for Cingulate Inc. (CING) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.04%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-7.04%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is 24.75 USD with a low forecast of 8.00 USD and a high forecast of 61.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.700

Low

8.00

Averages

24.75

High

61.00

Current: 3.700

Low

8.00

Averages

24.75

High

61.00

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$11 -> $10

2025-08-20

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$11 -> $10

2025-08-20

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $10 from $11 but keeps a Buy rating on the shares. The firm's post-Q2 call with the company's management has further strengthened its conviction for CTx-1301 regulatory acceptance in October and potential approval by mid-2026, the analyst tells investors in a research note. Assuming the NDA receives acceptance with an assigned PDUFA date, Roth expects a slew of launch preparation activities focused on disseminating CTx-1301's value in the crowded ADHD market, the firm added.

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$12 -> $11

2025-05-18

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$12 -> $11

2025-05-18

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $11 from $12 and keeps a Buy rating on the shares post the Q1 report. The firm says its discussions with management further bolstered its conviction for CTx-1301 application filing, which it expects to occur in Q3. Roth's base case assumes CTx-1301 FDA approval by Q4 of 2026 and launch by the first half of 2027.

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$75 → $60

2025-04-21

Reason

Ascendiant Capital

Edward Woo

Price Target

$75 → $60

2025-04-21

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$20

2025-03-06

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$20

2025-03-06

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$8 → $20

2025-01-30

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$8 → $20

2025-01-30

Maintains

Strong Buy

Reason

Roth MKM

Boobalan Pachaiyappan

Strong Buy

Initiates

$12

2025-01-10

Reason

Roth MKM

Boobalan Pachaiyappan

Price Target

$12

2025-01-10

Initiates

Strong Buy

Reason

Roth MKM initiated coverage of Cingulate with a Buy rating and $12 price target. The firm's optimism is driven by CTx-1301's Phase 3 data demonstrating entire active day efficacy in ADHD patients with an "industry-leading" average effect size. The company's current pro forma cash position and potential near-term dilution could be balanced by CTx-1301's new drug filing in mid-2025 and the potential to garner $1.6B in sales in 2035, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cingulate Inc (CING.O) is -1.41, compared to its 5-year average forward P/E of -9.14. For a more detailed relative valuation and DCF analysis to assess Cingulate Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.14

Current PE

-1.41

Overvalued PE

53.95

Undervalued PE

-72.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.17

Current PS

129.55

Overvalued PS

31.45

Undervalued PS

-21.11